Publication & Citation Trends
Most Cited Works
Publications
352 total
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma PDF
Cited by 1,525
OpenAlex
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Cited by 315
OpenAlex
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis PDF
Cited by 268
OpenAlex
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
Cited by 230
OpenAlex
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
Cited by 168
OpenAlex
Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index PDF
Cited by 241
OpenAlex
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib PDF
Cited by 138
OpenAlex
Research Topics
Colorectal Cancer Treatments and Studies
(84)
Gastric Cancer Management and Outcomes
(46)
Lung Cancer Treatments and Mutations
(42)
Hepatocellular Carcinoma Treatment and Prognosis
(39)
HER2/EGFR in Cancer Research
(36)
Frequent Co-Authors
Affiliations
AstraZeneca (United Kingdom)
Ulsan College
Seoul National University of Science and Technology
Brigham and Women's Hospital
Harvard University